Stephen W. Potter
Corporate Officer/Principal chez APPLIED GENETIC TECHNOLOGIES CORPORATION
Profil
Stephen W.
Potter currently works at Beacon Therapeutics (USA), Inc., as Chief Business Officer & Vice President from 2015.
Mr. Potter also formerly worked at Osiris Therapeutics, Inc., as SVP-Operations & Corporate Development from 2011 to 2012, Genzyme Corp., as Senior VP-Corporate & Business Development from 2006 to 2010, NeoStem, Inc., as Executive Vice President from 2013 to 2015, and Caladrius Biosciences, Inc., as Executive Vice President from 2013 to 2015.
Mr. Potter received his undergraduate degree in 1979 from the University of Massachusetts and Masters Business Admin degree from Harvard Business School.
Postes actifs de Stephen W. Potter
| Sociétés | Poste | Début |
|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Corporate Officer/Principal | 01/01/2015 |
Anciens postes connus de Stephen W. Potter
| Sociétés | Poste | Fin |
|---|---|---|
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Director/Board Member | 30/07/2013 |
| NeoStem, Inc. /Old/ | Director/Board Member | 01/07/2013 |
| OSIRIS THERAPEUTICS, INC. | Chief Operating Officer | 01/11/2012 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2010 |
Formation de Stephen W. Potter
| University of Massachusetts | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
| NeoStem, Inc. /Old/ | Transportation |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
